Establishment and Development:

The Medical and Pharmaceutical Basic Research Innovation Center of Emergency and Critical Care Medicine, the China's Ministry of Education and Shandong Provincial Engineering Research Center for Emergency Medicine was born from a shared vision and passion for acute chest pain as the main cause of critical cardiovascular diseases, cardiac arrest and cardiopulmonary resuscitation, acute organ injury and protection, research and development of innovative medicines and intelligent emergency equipment, medical big data and artificial intelligence, and basic research on zero magnetic medicine. Recognizing the need for that cardiovascular diseases are an important group of acute high-risk cardiogenic chest pain, which is the "number one killer" of patients, our founders decided to establish a laboratory dedicated to research on the mechanism and translational research of acute and critical cardiovascular disease，protect important organ function and severe infection and sepsis. The journey of our lab began with the Institute of Emergency and Critical Care Medicine of Shandong University based on the discipline of Emergency Medicine, established by Prof. Yuguo Chen. With a small but dedicated team, we set out to establish a research laboratory that would be recognized for its excellence and impact. Since its inception, our lab has gone through a remarkable journey of growth and development. We have created a key technology system for rapid, stratified and precise treatment of acute cardiogenic chest pain, which serves the realization of the major strategic goal of "Healthy China 2030". We have expanded our team to include 4 doctoral supervisors and 9 Master’s supervisors who are engaged in emergency medicine, cardiology and basic medicine. Additionally, we have forged valuable collaborations and partnerships with Academician Yihai Cao, Academician Jiancheng Fang and Academician Yun Zhang.

Team Members:

Our team is composed of 1 Taishan Scholar Climbing Program Expert, 1 National Nature Science Fund for Distinguished Young Scholars, 1 National Ten Thousand Talent Program for Young Top-notch Talents, 1 winner of China Youth Science and Technology Award, 2 chief scientists of national major projects, 2 Outstanding Contribution Experts of the National Health Commission, 11 Taishan Scholar Youth Experts, 1 Qilu Young Scholar, and 4 Qilu Health and Wellness Outstanding Young Talent of Shandong Province. Our team has undertaken more than 50 national, ministerial, and provincial projects, including 4 national key R&D projects, 1 National Special Investigation on Basic Scientific and Technological Resources, 1 National Nature Science Foundation Outstanding Youth Science Fund Project, and 1 National Natural Science Foundation key project. Yueguo Chen， the leader of Emergency Department, is the fellow of the American Society of Cardiology (FACC), the American Society of Cardiovascular Angiography and Intervention (FSCAI), the European Society of Cardiology (FESC) and the Hong Kong College of Emergency Medicine. He is the chairman of the 9th Emergency Medicine Branch of the Chinese Medical Association. Together, they work tirelessly to acute chest pain as the main cause of critical cardiovascular diseases, cardiac arrest and cardiopulmonary resuscitation, acute organ injury and protection, research and development of innovative medicines and intelligent emergency equipment, medical big data and artificial intelligence, and basic research on zero magnetic medicine.

Research Areas:

The Medical and Pharmaceutical Basic Research Innovation Center of Emergency and Critical Care Medicine, the China's Ministry of Education and Shandong Provincial Engineering Research Center for Emergency Medicine specializes in acute chest pain as the main cause of critical cardiovascular diseases, cardiac arrest and cardiopulmonary resuscitation, acute organ injury and protection, research and development of innovative medicines and intelligent emergency equipment, medical big data and artificial intelligence, and basic research on zero-magnetism medicine.

Research Achievements:

We have made significant contributions in emergency and severe diseases involving basic research, clinical research, and medical-engineering research. Our team has undertaken more than 50 national, ministerial, and provincial projects, including 4 national key R&D projects, 1 National Special Investigation on Basic Scientific and Technological Resources, 1 National Nature Science Foundation Outstanding Youth Science Fund Project, and 1 National Natural Science Foundation key project. We have published over 200 SCI papers, including Circulation, Eur Heart J, JAMA, JAMA Cardiol, and Nature Communication, edited or co-edited over 10 textbooks including national planned textbooks of Emergency Medicine, chaired the formulation of more than 10 national and international guidelines or consensus, obtained over 20 national patents. The team have received over 10 provincial and ministerial-level science and technology awards, including the first prize of the Chinese Medical Science and Technology Award and the first prize of the Shandong Province Science and Technology Progress Award.

Main Publications:

1. Zhai X, Cao S, Wang J, Qiao B, Liu X, Hua R, Zhao M, Sun S, Han Y, Wu S, Pang J, Yuan Q, Wang B, Xu F, Wei S, Chen Y. Carbonylation of Runx2 at K176 by 4-Hydroxynonenal Accelerates Vascular Calcification. Circulation. 2024 Feb 13.

2. Yang K, Ren J, Li X, Wang Z, Xue L, Cui S, Sang W, Xu T, Zhang J, Yu J, Liu Z, Shang H, Pang J, Huang X, Chen Y, Xu F. Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype. Eur Heart J. 2020 Jul 7;41(26):2442-2453.

3. Yang K, Cui S, Wang J, Xu T, Du H, Yue H, Ye H, Guo J, Zhang J, Li P, Guo Y, Pan C, Pang J, Wang J, Yu X, Zhang C, Liu Z, Chen Y, Xu F. Early Progression of Abdominal Aortic Aneurysm is Decelerated by Improved Endothelial Barrier Function via ALDH2-LIN28B-ELK3 Signaling. Adv Sci (Weinh). 2023 Nov;10(32):e2302231.

4. Liu L, Pang J, Qin D, Li R, Zou D, Chi K, Wu W, Rui H, Yu H, Zhu W, Liu K, Wu X, Wang J, Xu P, Song X, Cao Y, Wang J, Xu F, Xue L, Chen Y. Deubiquitinase OTUD5 as a Novel Protector against 4-HNE-Triggered Ferroptosis in Myocardial Ischemia/Reperfusion Injury. Adv Sci (Weinh). 2023 Oct;10(28):e2301852.

5. Liu H, Yin H, Wang Z, Yuan Q, Xu F, Chen Y, Li C. Rho A/ROCK1 signaling-mediated metabolic reprogramming of valvular interstitial cells toward Warburg effect accelerates aortic valve calcification via AMPK/RUNX2 axis. Cell Death Dis. 2023 Feb 11;14(2):108.

6. Zhang J, Guo Y, Zhao X, Pang J, Pan C, Wang J, Wei S, Yu X, Zhang C, Chen Y, Yin H, Xu F. The role of aldehyde dehydrogenase 2 in cardiovascular disease. Nat Rev Cardiol. 2023 Jul;20(7):495-509.

7. Zheng J, Lv C, Zheng W, Zhang G, Tan H, Ma Y, Zhu Y, Li C, Han X, Yan S, Pan C, Zhang J, Hou Y, Wang C, Bian Y, Liu R, Cheng K, Ma J, Zheng Z, Song R, Wang M, Gu J, McNally B, Ong MEH, Chen Y, Xu F; BASIC-OHCA Coordinators and Investigators. Incidence, process of care, and outcomes of out-of-hospital cardiac arrest in China: a prospective study of the BASIC-OHCA registry. Lancet Public Health. 2023 Dec;8(12):e923-e932.

8. Pan C, Xu C, Zheng J, Song R, Lv C, Zhang G, Tan H, Ma Y, Zhu Y, Han X, Li C, Yan S, Zheng W, Wang C, Zhang J, Bian Y, Ma J, Cheng K, Liu R, Hou Y, Chen Q, Zhao X, McNally B, Chen R, Kan H, Meng X, Chen Y, Xu F. Fine and coarse particulate air pollution and out-of-hospital cardiac arrest onset: a nationwide case-crossover study in China. J Hazard Mater. 2023 Sep 5;457:131829.

9. Wang H, Zhao S, Wang S, Zheng Y, Wang S, Chen H, Pang J, Ma J, Yang X, Chen Y. Global magnitude of encephalitis burden and its evolving pattern over the past 30 years. J Infect. 2022 Jun;84(6):777-787.

10. Pang J, Xu F, Aondio G, Li Y, Fumagalli A, Lu M, Valmadre G, Wei J, Bian Y, Canesi M, Damiani G, Zhang Y, Yu D, Chen J, Ji X, Sui W, Wang B, Wu S, Kovacs A, Revera M, Wang H, Jing X, Zhang Y, Chen Y, Cao Y. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun. 2021 Feb 5;12(1):814.

Facilities & Resources:

Our state-of-the-art facilities and cutting-edge technology enable us to conduct research that is both rigorous and innovative. We have over 200 pieces of equipment, including 25 valued at more than 500,000 yuan, with a total original value of over 30 million yuan. We focus on our main research direction and have built ten central featured platforms including cardiovascular featured research, microscopic characterization, flow sorting, immunohistochemistry, cell biology, molecular biology experimental, energy metabolism platform, drug synthesis, zero magnetic medicine basic research, and physiology analysis. Based on the platform, we have gradually established the following technology systems, including cell biology, molecular biology, morphology, flow cytometry, animal model construction and translational research-related technologies. In addition, we have an emergency and critical biobank platform, covering an area of more than 1000 m².

Collaborations & Partnerships:

We believe in the power of collaboration. That's why we have forged partnerships with leading universities such as Karolinska Medical College, Harvard Medical School, the University of Wyoming and the University of Michigan. To further advance our research. Our lab is active in international scientific and technological exchange activities, and participated in a number of large-scale international academic conferences every year supported by Shandong Branch of Emergency Medicine, providing an academic exchange platform for global professionals. We also invited experts from the United States, Austria and other countries and regions through the short-term overseas expert project to conduct nearly 30 lectures.

Recreational Activities:

The laboratory has a pleasant environment, featuring a tea break room and a rest area. Additionally, there are multiple meeting rooms equipped with conference systems for efficient and professional meetings. Our lab also organizes team-building activities to enhance the friendship among lab members. E.g. social gatherings, sports and fitness activities, cultural events, festivals and celebrations, professional development workshops.

Other Features:

Cardiovascular characteristic platform is an important research base for basic and translational medicine of cardiovascular diseases. With the goal of translational medicine and the orientation of clinical problems, we will solve major problems such as early warning and prediction of cardiovascular diseases, disease treatment and drug intervention.

The nanomedicine Research platform is committed to building a technology research and transformation platform for the prevention, diagnosis and treatment of major diseases such as cardiovascular and cerebrovascular diseases, inflammation and infection.

Zero magnetic medical basic research platform mainly focuses on the basic research of zero magnetic medicine, provides technical support and experimental basis related to zero magnetic medicine.

Contact:

For more information or inquiries, please contact us at jiaojiaopang@126.com.